Researchers are studying the best ways to train healthcare providers to support patients using semaglutide
Novel foods authorisation guidance
Although the existing evidence in HFpEF is compelling, further trials seem warranted, particularly with respect to the effects of GLP-1 RAs on clinical outcomes and, possibly, in broader patient populations, such as patients with HFrEF or those without obesity.
Especficamente, en el estudio SELECT, el uso de semaglutida 2.4 mg redujo un 20% el riesgo de ACV no fatal, infarto no fatal y muerte cardiovascular, y un 19% el riesgo de muerte por cualquier causa
These findings indicate that the increased anxiety-like behaviors observed in heroin withdrawal mice is correlated with elevated protein expression levels of GLP-1, TrkB, BDNF, and other associated proteins